482 related articles for article (PubMed ID: 36810086)
21. The genetic alteration spectrum of the SWI/SNF complex: The oncogenic roles of BRD9 and ACTL6A.
Sima X; He J; Peng J; Xu Y; Zhang F; Deng L
PLoS One; 2019; 14(9):e0222305. PubMed ID: 31504061
[TBL] [Abstract][Full Text] [Related]
22. The SWI/SNF complex regulates the expression of miR-222, a tumor suppressor microRNA in lung adenocarcinoma.
Peinado P; Andrades A; Martorell-Marugán J; Haswell JR; Slack FJ; Carmona-Sáez P; Medina PP
Hum Mol Genet; 2021 Nov; 30(23):2263-2271. PubMed ID: 34240140
[TBL] [Abstract][Full Text] [Related]
23. Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities.
Orlando KA; Nguyen V; Raab JR; Walhart T; Weissman BE
Expert Rev Anticancer Ther; 2019 May; 19(5):375-391. PubMed ID: 30986130
[TBL] [Abstract][Full Text] [Related]
24. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Kim KH; Kim W; Howard TP; Vazquez F; Tsherniak A; Wu JN; Wang W; Haswell JR; Walensky LD; Hahn WC; Orkin SH; Roberts CW
Nat Med; 2015 Dec; 21(12):1491-6. PubMed ID: 26552009
[TBL] [Abstract][Full Text] [Related]
25. SWI/SNF complex-deficient soft tissue neoplasms: An update.
Schaefer IM; Hornick JL
Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
[TBL] [Abstract][Full Text] [Related]
26. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
27. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
28. SWI/SNF deficient central nervous system neoplasms.
Cai C
Semin Diagn Pathol; 2021 May; 38(3):167-174. PubMed ID: 33762087
[TBL] [Abstract][Full Text] [Related]
29. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
30. Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities.
St Pierre R; Kadoch C
Curr Opin Genet Dev; 2017 Feb; 42():56-67. PubMed ID: 28391084
[TBL] [Abstract][Full Text] [Related]
31. The spectrum of SWI/SNF mutations, ubiquitous in human cancers.
Shain AH; Pollack JR
PLoS One; 2013; 8(1):e55119. PubMed ID: 23355908
[TBL] [Abstract][Full Text] [Related]
32. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
Watanabe R; Ui A; Kanno S; Ogiwara H; Nagase T; Kohno T; Yasui A
Cancer Res; 2014 May; 74(9):2465-75. PubMed ID: 24788099
[TBL] [Abstract][Full Text] [Related]
33. SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models.
Wang Y; Hoang L; Ji JX; Huntsman DG
Annu Rev Pathol; 2020 Jan; 15():467-492. PubMed ID: 31977292
[TBL] [Abstract][Full Text] [Related]
34. SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases.
Li Y; Yang X; Zhu W; Xu Y; Ma J; He C; Wang F
Cancer Cell Int; 2022 Nov; 22(1):347. PubMed ID: 36371186
[TBL] [Abstract][Full Text] [Related]
35. Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
Pyziak K; Sroka-Porada A; Rzymski T; Dulak J; Łoboda A
Drug Dev Res; 2021 Sep; 82(6):730-753. PubMed ID: 33565092
[TBL] [Abstract][Full Text] [Related]
36. Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits.
Raab JR; Runge JS; Spear CC; Magnuson T
Epigenetics Chromatin; 2017 Dec; 10(1):62. PubMed ID: 29273066
[TBL] [Abstract][Full Text] [Related]
37. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes.
Alpsoy A; Dykhuizen EC
J Biol Chem; 2018 Mar; 293(11):3892-3903. PubMed ID: 29374058
[TBL] [Abstract][Full Text] [Related]
38. SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors.
Panwalkar P; Pratt D; Chung C; Dang D; Le P; Martinez D; Bayliss JM; Smith KS; Adam M; Potter S; Northcott PA; Mascarenhas L; Shows J; Pawel B; Margol A; Huang A; Judkins AR; Venneti S
Neuro Oncol; 2020 Jun; 22(6):785-796. PubMed ID: 31912158
[TBL] [Abstract][Full Text] [Related]
39. BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor?
Jancewicz I; Siedlecki JA; Sarnowski TJ; Sarnowska E
Epigenetics Chromatin; 2019 Nov; 12(1):68. PubMed ID: 31722744
[TBL] [Abstract][Full Text] [Related]
40. BCL7A-containing SWI/SNF/BAF complexes modulate mitochondrial bioenergetics during neural progenitor differentiation.
Wischhof L; Lee HM; Tutas J; Overkott C; Tedt E; Stork M; Peitz M; Brüstle O; Ulas T; Händler K; Schultze JL; Ehninger D; Nicotera P; Salomoni P; Bano D
EMBO J; 2022 Dec; 41(23):e110595. PubMed ID: 36305367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]